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PRIORITY COMMUNICATIONAssociation Among Clinical Response, Hippocampal
Volume, and FKBP5 Gene Expression in Individuals
with Posttraumatic Stress Disorder Receiving
Cognitive Behavioral Therapy
Einat Levy-Gigi, Csilla Szabó, Oguz Kelemen, and Szabolcs KériBackground: Posttraumatic stress disorder (PTSD) is characterized by a reduced expression of FKBP5, a key modulator of the
glucocorticoid receptor. Smaller hippocampal volume has also been documented in PTSD. We explored possible changes in FKBP5 gene
expression and brain structure in patients with PTSD after cognitive behavioral therapy (CBT).
Methods: We measured peripheral FKBP5 RNA and volumes of the hippocampus, amygdala, and medial orbitofrontal cortex in 39
patients with PTSD before and after CBT. The control subjects were 31 trauma-exposed individuals without PTSD who were also assessed
twice. Gene expression changes were screened with a microarray toolkit, which was followed by quantitative polymerase chain reaction
for FKBP5 RNA. Brain volumes were measured using FreeSurfer.
Results: At baseline, patients with PTSD showed lower FKBP5 gene expression and smaller hippocampal and medial orbitofrontal cortex,
but not amygdala, volumes relative to control subjects. At follow-up, we found signiﬁcantly increased FKBP5 expression and increased
hippocampal volume in patients with PTSD. At follow-up, patients did not differ from control subjects in hippocampal volume.
Improvement in PTSD symptoms was predicted by increased FKBP5 expression and increased hippocampal volume, but the primary
predictor was FKBP5 expression. The most signiﬁcantly altered gene expression in patients with PTSD relative to control subjects was
found for ribosomal protein S6 kinase, which did not change after CBT and did not correlate with hippocampal volume.
Conclusions: Clinical improvement in individuals with PTSD was associated with increased expression of FKBP5 and increased
hippocampal volume, which were positively correlated.Key Words: Cognitive behavioral therapy, FKBP5, gene
expression, hippocampus, posttraumatic stress disorder,
structural brain imagingIn spite of extensive research focusing on the mechanism andtreatment of posttraumatic stress disorder (PTSD), the neuro-biological correlates of symptom improvement during psycho-
therapy remain elusive. Results from brain imaging studies and
animal models suggest that the medial prefrontal cortex, amyg-
dala, and hippocampus play a role in the development of PTSD.
These brain areas are involved in fear conditioning, extinction,
emotion regulation, and spatiotemporal context representation
(i.e., where and when the traumatic event occurred) (1–4).
Pioneering studies found smaller hippocampal volumes in PTSD
associated with combat-related trauma and childhood abuse
[(5,6); for meta-analytic evidence, see (3,7–9)]. Additional gray
matter reductions have been identiﬁed in anterior cingulate
cortex, ventromedial prefrontal cortex, and left temporal pole/
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http://dx.doi.org/10.1016/j.biopsych.2013.05.017Functional brain imaging studies, using different tasks or a
resting state paradigm during scanning, revealed increased
activation in widespread prefrontal and cingulate areas as a
potential impact of cognitive behavioral therapy (CBT) in PTSD,
although the results are inconsistent [for a review, see (10)]. In
contrast to the results of functional brain imaging studies,
morphological changes associated with psychotherapy were
conﬁned to the hippocampal formation and cingulate cortex
[(11–13)] but see (14); reviewed in (10)].
The molecular correlates of these changes are unknown. The
role of the overactive hypothalamic-pituitary stress axis has been
implicated in PTSD (15), and alteration of the homeostatic
regulation of cortisol may lead to structural changes, such as
hippocampal atrophy (16,17). There is an abundance of potential
target molecules, but FKBP5 (FK506 binding protein) may be a
special hub in complex molecular networks, and multifaceted
evidence suggests its role in the pathophysiology of mood
disorders and PTSD (18). FKBP5 binds to the glucocorticoid
receptor complex, reducing the afﬁnity of cortisol and the nuclear
translocation of the receptor (18). In mice, deletion of the FKBP5
gene increased the sensitivity of the hypothalamic-pituitary axis
for negative feedback by glucocorticoids, leading to a lower
cortisol level after acute stress, which is similar to PTSD (19).
Genetic polymorphisms of the FKBP5 gene have been shown to
be associated with anxiety and mood disorders, including PTSD,
interacting with environmental adverse events [e.g., (20–23)].
These genetic factors and related molecular mechanisms, as well
as pre-existing structural brain alterations, might predict the
development of future PTSD (24–27).
Segman et al. (28) found that the degree of FKBP5 gene
expression within a few hours after a traumatic event correlated
signiﬁcantly with the severity of acute PTSD-like symptoms.BIOL PSYCHIATRY 2013;74:793–800
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patients surviving the World Trade Center attacks compared with
individuals without PTSD. Other research groups conﬁrmed and
extended these ﬁndings (30,31). Animal models suggest that the
FKBP5 gene is expressed where glucocorticoid receptors are also
abundant, including the hippocampal formation and the central
amygdala (32).
In the present study, we aimed to explore morphological
changes of brain areas linked to the symptoms of PTSD before and
after CBT. In addition, we compared the clinical and morphological
changes with peripheral gene expression patterns. We measured
the volume of the medial orbitofrontal cortex (mOFC), hippo-
campus, and amygdala before and after CBT and compared brain
volume and symptom changes. Although there is no parsimonious
meta-analytic evidence for altered amygdalar volume in PTSD (33),
recent large-scale studies reported contradictory but signiﬁcant
ﬁndings (smaller versus enlarged amygdala in PTSD) (34,35).
Therefore, we included amygdala in the analysis. Regarding the
gene expression pattern, we ﬁrst screened PTSD patients using a
microarray platform, which was followed by quantitative polymer-
ase chain reaction (qPCR). Speciﬁcally, we intended to replicate
the altered expression of the FKBP5 gene.
We had two main hypotheses. In PTSD patients who underwent
CBT, there will be increased levels of FKBP5 messenger RNA relative
to the pre-CBT baseline condition. This hypothesis was based on the
ﬁnding that, in contrast to patients with active symptoms, remitted
patients with PTSD did not exhibit signiﬁcantly diminished FKBP5
gene expression (30). Given that FKBP5 may be related to glucocorti-
coid and stress response in the hippocampus (32,36) and the
expression of glucocorticoid-related genes (GLIZ [glucocorticoid-
induced leucine zipper], SGK-1 [serum- and glucocorticoid-induced
protein kinase-1]) are associated with hippocampal atrophy in
depression (37), we hypothesized a relationship between changes
in hippocampal volume and FKBP5 expression (increased hippo-
campal volume associated with increased FKBP5 expression after CBT
relative to pre-CBT baseline).Methods and Materials
Participants and Psychological Assessment
We enrolled 47 previously untreated patients with PTSD and
31 trauma-exposed non-PTSD volunteers of Caucasian origin at
the early trauma intervention center (National Psychiatry Center,
Budapest, Hungary). Thirty-nine patients with PTSD completed
the study (Table 1). Volunteers were referred by general practi-
tioners, clinical psychologists, psychiatrists, and social workers
who were trained to recognize probable PTSD using the Primary
Care PTSD Screen (38). Additionally, volunteers could contact the
center directly via telephone or e-mail. After psychoeducation
and description of research, we offered the following opportu-
nities: 1) CBT only (supplemented by pharmacologic interventions
if needed and agreed); 2) CBT plus participation in research;
3) regular psychiatric treatment; and 4) none. The 47 patients
enrolled in this study chose the second option. Twenty-seven
patients not reported here chose another option. For psycholog-
ical assessment, we administered the Structured Clinical Interview
for DSM-IV Axis I Disorders, Clinician Version (39), the Trauma and
Life Events Self-Report Inventory (40), the Clinician-Administered
PTSD Scale (CAPS) (41), the Hamilton Depression Rating Scale (42),
and the Wechsler Abbreviated Scale of Intelligence (43). All scales
were administered by trained and regularly supervised clinical
psychologists who were blind to the aim of the study. Thewww.sobp.org/journaldiagnosis was conﬁrmed by two independent experts. Exclusion
criteria included history of psychiatric or neurological disorders
and current comorbid DSM-IV mood disorders, psychotic disor-
ders, and substance misuse. Four patients with PTSD had
comorbid panic disorder and speciﬁc phobia. The demographic
and clinical data, including trauma type and duration of symp-
toms, are presented in Table 1. The study was carried out in
accordance with the Declaration of Helsinki and it was approved
by the local ethics board (TUKEB 65/2010). All participants gave
written informed consent.
Procedure
At the ﬁrst assessment, patients with PTSD and trauma-exposed
control subjects underwent psychological assessment, brain mag-
netic resonance imaging, and blood sample drawing. After this
assessment, patients with PTSD received trauma-focused CBT
according to the protocol of Marks et al. (44) [for Hungarian
applications, see (45)]. Cognitive behavioral therapy helps identify,
challenge, and modify negative automatic thoughts and malad-
aptive cognitive schemas. Participants learned how to identify
dysfunctional automatic thoughts and cognitive distortions, ﬁnd
evidences for and against thoughts, create alternatives, and ﬁnally
reappraise their beliefs about themselves and the trauma by
creating a new narrative of the traumatic event. Following a
psychoeducation section on PTSD, patients learned to detect their
automatic thoughts using daily monitoring and diaries. During
homework sections, patients prepared regular thought records
and audiotaped their sessions (44,45). Clinical psychologists or
psychiatrists with adequate training, regular supervision, and certif-
ication of Good Clinical Practice administered 12 weekly 1.5-hour
sessions. We measured the clinicians’ adherence to treatment
protocol by videotaping and independent ratings. The control
subjects did not participate in any psychological intervention. We
preferred CBT instead of prolonged exposure therapy because most
of the patients expressed concerns, anxiety, and discomfort after the
description of exposure-based intervention. After the 12-week
period, patients with PTSD and control subjects were re-assessed,
including magnetic resonance imaging and blood sample drawing.
Investigators analyzing imaging and molecular data were blind to
diagnosis and time point of investigation. Clinical scales, interviews,
and CBT sessions were administered by experts who were naïve to
the aim of the study and did not have information on brain imaging
and molecular data.
From the 47 patients with PTSD, 39 completed the study. The
remaining eight patients decided to stop the CBT sessions and
continued treatment according to the ofﬁcial protocol used in
psychiatric practice, including antidepressant medications. The 39
patients who completed CBT did not receive antidepressant
medications. Sixteen patients received benzodiazepines for less
than 4 weeks to ameliorate sleep disorder and daytime anxiety, as
well as beta blockers to reduce autonomic symptoms of anxiety
and arousal. The changes in clinical symptoms across the two
assessment points are shown in Table 1.
Structural Brain Imaging
We used the standard FreeSurfer protocol for structural
neuroimaging (Martinos Center for Biomedical Imaging, Boston,
Massachusetts; http://surfer.nmr.mgh.harvard.edu; version: v5.1.0,
Dell XPS workstation; Dell Inc., Austin, Texas). We applied a multiecho
FLASH sequence with a 1 mm3 isotropic resolution (Siemens Trio 3T
scanner [Munich and Berlin, Germany]) (256  256 matrix, 176 sagittal
slices with a thickness of 1 mm, repetition time 2530 msec,
inversion time 1100 msec, echo time 1.64/3.5/5.36/7.22 msec,
Table 1. Clinical and Demographic Characteristics
PTSD Trauma-Exposed Control Subjects
(N ¼ 39; 30 Female Subjects, 9 Male Subjects) (N ¼ 31; 20 Female Subjects; 11 Male Subjects)
Type of Trauma Environmental disaster Environmental disaster
(red sludge and ﬂood): n ¼ 12 (red sludge and ﬂood): n ¼ 10
Violent crime: n ¼ 8 Violent crime: n ¼ 5
Trafﬁc accident: n ¼ 13 Trafﬁc accident: n ¼ 10
Combat: n ¼ 3 Combat: n ¼ 3
Emergency service workers: n ¼ 3 Emergency service workers: n ¼ 3
Smoking n ¼ 14 n ¼ 12
Occasional Alcohol Consumption n ¼ 25 n ¼ 23
Mean SD Mean SD
Age (Years) 35.9 12.0 37.0 10.4
Education (Years) 11.6 2.9 11.4 2.7
IQ 110.6 12.2 108.8 8.9
Trauma and Life Events Self-Report Inventory 6.3 2.5 5.4 1.7
Duration of Symptoms (Months) 3.8 2.5
Time Since Trauma (Months) 8.9 2.4
Before Cognitive
Behavioral Therapy
After Cognitive
Behavioral Therapy
Mean SD Mean SD
Clinician-Administered PTSD Scale
Re-experiencea 15.6 6.9 10.3 6.9
Avoidancea 22.2 6.6 14.3 6.6
Arousala 24.6 5.2 15.8 7.0
Totala 62.4 12.8 40.4 20.3
Hamilton Depression Rating Scaleb 15.3 8.2 11.2 8.3
Patients with posttraumatic stress disorder (PTSD) and trauma-exposed control subjects did not differ in gender distribution, smoking, occasional
alcohol use (chi-square tests, p  .1), age, education, and IQ (t tests, p  .1). Cognitive behavioral therapy was applied only in PTSD patients. Trauma-
exposed control subjects did not receive psychological treatment.
ap  .0005.
bp  .05.
E. Levy-Gigi et al. BIOL PSYCHIATRY 2013;74:793–800 795bandwidth 651 Hz, nonselective excitation at 71). Automated image
processing consisted of the following steps: removal of nonbrain
tissue with a hybrid watershed/surface deformation procedure,
automated Talairach transformation, and segmentation of white and
gray matter (46). We also used laser alignment to optimize the
standardization of head position across participants and assessments.
The dependent measures were as follows: right and left hippocampus,
amygdala, mOFC, intracranial volume, and total brain volume. These
brain regions have been deﬁned previously in the FreeSurfer protocol,
and reliable and replicable volume measurements have been
established (47,48) (http://surfer.nmr.mgh.harvard.edu). The accuracy
of each FreeSurfer region of interest (ROI) was visually inspected. In a
pilot study, we also performed the manual parcellation of these ROIs
in 20 healthy control subjects. The intraclass correlation coefﬁcient
describing the correlation of FreeSurfer and manual parcellation
methods were high (r  .8 for each ROI). We used the same
computer (Dell XPS) and operation system (Linux; GNU/Linux, Free
Software Foundation) for all measurements to avoid any bias
stemming from different systems (49). Region of interest volumes
were corrected for total intracranial volume (50).
Gene Expression and Plasma Cortisol
We adapted the method of Yehuda et al. (29). For the sake of
comparability between the studies, we followed their procedure
exactly, and therefore the technical details will not be described
herein. We drew fasting blood samples between 08:00 and 09:00
hours. For screening, we used Human Genome U133 Plus 2.0Array (Affymetrix, Santa Clara, California), which was followed by
qPCR for FKBP5 expression. At the second assessment, we
performed FKBP5 qPCR to study its potential changes after CBT.
For a control analysis, we examined the factor that showed the
most signiﬁcantly altered expression in PTSD. This control analysis
was hypothesis free. Serum cortisol concentration was measured
at both assessments with a commercial radioimmunoassay kit
(Diagnostic Systems Laboratories, Webster, Texas).
Data Analysis
We used STATISTICA 11 software for data analysis (StatSoft,
Inc., Tulsa, Oklahoma). First, data were entered into Kolmogorov-
Smirnov and Levene’s tests to verify normal distribution and
homogeneity of variance, respectively. Second, we used repeated
measures analyses of variance (ANOVAs) on ROI volumes. These
ANOVAs investigated the main effects of group (PTSD vs. control
subjects), assessment session (before vs. after CBT in patients,
baseline vs. follow-up in control subjects), laterality (left vs. right),
and their interactions. All ROI volumes were corrected for intra-
cranial volume. Whole brain volume was included as a covariate
in the ANOVAs. A similar ANOVA design was used for the analysis
of FKBP5 expression without laterality and volume corrections.
Tukey’s honestly signiﬁcant difference (HSD) tests were used for
post hoc comparisons. We calculated Pearson’s product moment
correlation coefﬁcients and performed multiple regression anal-
yses to explore the relationship between changes in PTSD
symptoms, FKBP5 expression, and hippocampal volume.www.sobp.org/journal
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Clinical and demographic data were compared with chi-square
tests and two-tailed Student t tests. The level of statistical
signiﬁcance was set at α  .05.Figure 1. Hippocampal volume (mm3) in patients with posttraumatic
stress disorder (PTSD) and control subjects. Error bars indicate 95%
conﬁdence intervals. There were signiﬁcant bilateral differences between
patients and control subjects only before cognitive behavioral therapy
(p  .005, Tukey’s honestly signiﬁcant difference test).Results
Structural Brain Imaging
The ANOVA conducted on the hippocampal volume revealed
a signiﬁcant main effect of group (PTSD vs. control subjects,
F1,68 ¼ 8.18, p  .05, η2 ¼ .11). There was a signiﬁcant interaction
between group and assessment session (before and after CBT in
patients) (F1,68 ¼ 13.29, p  .005, η2 ¼ .14). The effect of laterality
(left vs. right hippocampus) and its interactions with group and
assessment session were not signiﬁcant (all p values  .3).
Tukey’s HSD conducted on the group by assessment session
interaction indicated signiﬁcantly smaller hippocampal volumes
in patients with PTSD relative to control subjects at the ﬁrst
assessment (before CBT) (p  .005). This difference was not
observed at the second assessment (after CBT) (p  .3). There
were greater hippocampal volumes in patients with PTSD at the
second assessment relative to the ﬁrst assessment (p  .05). In
control subjects, hippocampal volumes did not differ across
assessments (p  .2) (Figure 1).
For mOFC volume, we also found a main effect of group
(F1,68 ¼ 5.64, p  .05, η2 ¼ .08), indicating a reduced volume in
patients relative to control subjects, but the remaining main
effects and interactions did not reach the level of statistical
signiﬁcance (all p values  .1). For amygdala and total brain
volume, none of the main effects or interactions appeared
signiﬁcant (all p values  .2) (Table 2).
Gene Expression
At the ﬁrst assessment, we replicated several differentially
expressed transcripts in PTSD patients compared with control
subjects, as reported by Yehuda et al. (29) (data not shown because
this is beyond the scope of the study). The ANOVA conducted on
the level of FKBP5 expression measured by qPCR revealed signiﬁcant
main effects of group (F1,68 ¼ 18.0, p  .001, η2 ¼ .21) and
assessment session (F1,68 ¼ 12.2, p  .005, η2 ¼ .14). The two-way
interaction between group and assessment session was also
signiﬁcant (F1,68 ¼ 6.26, p  .05, η2 ¼ .08).Table 2. Structural MRI Results
First Assessment
PTSD (n ¼ 39) Control Subj
Mean SD Mean
Right Hippocampusa 4698.7 253.3 4905.8
Left Hippocampusa 4632.1 247.7 4821.8
Right Amygdala 1728.9 103.9 1703.9
Left Amygdala 1683.7 107.2 1665.6
Right Medial Orbitofrontal Cortexb 5338.2 484.9 5642.4
Left Medial Orbitofrontal Cortexb 5311.5 518.4 5548.2
Total Brain Volume 1.5 .2 1.4
Intracranial Volume 1.7 .2 1.7
CBT, cognitive behavioral therapy; MRI, magnetic resonance imaging; PTSD
Data are in mm3 ( 106 for total brain volume and intracranial volume).
aSmaller volume in PTSD relative to control subjects, which was not obser
bSmaller volume in PTSD relative to control subjects, which was similar be
www.sobp.org/journalTukey’s HSD tests indicated lower FKBP5 expression in individuals
with PTSD relative to control subjects at the ﬁrst assessment (p 
.001), but this difference did not retain statistical signiﬁcance at the
second assessment (p¼ .06). In patients with PTSD, FKBP5 expression
increased across the ﬁrst and second assessment (p .001), whereas
in control subjects these values did not change (p ¼ .9) (Figure 2).
Serum Cortisol
There were statistically similar values in individuals with PTSD
and control subjects at both assessments (ﬁrst assessment PTSD:
14.6 μg/dL, SD ¼ 5.0; control subjects: 14.8 μg/dL, SD ¼ 5.8;
second assessment PTSD: 15.0 μg/dL, SD ¼ 5.2; control subjects:
14.5 μg/dL, SD ¼ 4.9; p  .5).
Correlations between Symptoms, Hippocampal Volume, and
FKBP5 Expression
First, we examined the correlation among total CAPS scores,
hippocampal volume, and FKBP5 expression before and after CBT.
We restricted this analysis to hippocampal volume because onlySecond Assessment
ects (n ¼ 31) PTSD (n ¼ 39) Control Subjects (n ¼ 31)
SD Mean SD Mean SD
228.5 4804.4 217.0 4836.0 205.6
211.7 4739.4 243.9 4751.0 207.7
113.5 1727.4 111.9 1710.0 109.7
116.7 1705.3 117.2 1674.0 122.2
487.3 5362.6 477.6 5632.1 498.4
486.9 5330.0 509.6 5531.9 461.7
.2 1.4 .2 1.4 .2
.1 1.7 .2 1.7 .1
, posttraumatic stress disorder.
ved after CBT.
fore and after CBT (for statistical details, see the text).
Figure 2. Peripheral FKBP5 expression from quantitative polymerase
chain reaction measurements. Error bars indicate 95% conﬁdence inter-
vals. There was a signiﬁcant difference between patients and control
subjects only before cognitive behavioral therapy (p  .001, Tukey’s
honestly signiﬁcant difference test). PTSD, posttraumatic stress disorder.
Figure 3. Correlations among Clinician-Administered PTSD Scale (CAPS)
total scores, total hippocampal volume (mm3), and FKBP5 RNA expression
after versus before cognitive behavioral therapy. Increased FKBP5 expres-
sion was associated with greater total hippocampal volume expansion
and better clinical improvement. Pearson’s correlation coefﬁcients: CAPS –
hippocampus: −.52, p  .005; CAPS – FKBP5: −.63, p  .001; hippocampus
– FKBP5: r ¼ .56, p  .001.
E. Levy-Gigi et al. BIOL PSYCHIATRY 2013;74:793–800 797this brain structure showed volume changes across assessments.
These correlation analyses revealed no signiﬁcant results (−.2  r
 .2, p  .1). Second, we examined the correlation between
changes in total CAPS scores, changes in total hippocampal
volume, and changes in FKBP5 expression (change: values after
CBT minus values before CBT). We found signiﬁcant correlations
between changes in CAPS scores and changes in FKBP5 expression
(r ¼ −.63, p  .001), changes in hippocampal volume and changes
in FKBP5 expression (r ¼ .56, p  .001), and changes in
CAPS scores and changes in hippocampal volume (r ¼ −.52,
p  .005) (Bonferroni-corrected level of signiﬁcance: .05/9 ¼ .006)
(Figure 3).
Regression analyses revealed that both changes in total
hippocampal volume and changes in FKBP5 expression signiﬁ-
cantly predicted changes in total CAPS scores (hippocampal
volume: b* ¼ −.52, t37 ¼ −3.69, p  .005, R2 ¼ .25; FKBP5:
b* ¼ −.63, t37 ¼ −4.92, p  .001, R2 ¼ .38). However, when both
changes in FKBP5 expression and changes in total hippocampal
volume were entered into the analysis, only changes in FKBP5
expression remained signiﬁcant as a primary predictor (b* ¼ .49,
t37 ¼ 3.26, p  .005, R2 ¼ .40).
Control Analyses
We examined the speciﬁcity of our ﬁndings for FKBP5. Instead
of a hypothesis-driven analysis, we investigated the factor
exhibiting the most signiﬁcantly altered expression in untreated
patients with PTSD relative to control subjects. This factor was
ribosomal protein S6 kinase (RPS6K) (90 kDa; Affy ID:
204633_s_at; p  .00001), which is in accordance with the
results of Yehuda et al. (29). Expression of RPS6K did not change
after CBT and did not correlate with hippocampal volumes
(−.1  r  .1, p  .5).
We also conducted some secondary analyses to test other factors
and confounders. There were no signiﬁcant correlations or predictive
relationships among CAPS scores and serum cortisol (p  .5).
Hamilton Depression Rating Scale scores did not correlate and
predict brain volumes and FKBP5 expression (p  .5). Demographic
parameters, as depicted in Table 1, did not predict symptom
reduction (p  .5).Discussion
The most noteworthy ﬁnding of this study was that clinical
improvement during CBT in PTSD was associated with increased
hippocampal size and elevated FKBP5 gene expression, a cellular
regulator of the glucocorticoid receptor. Increased hippocampal
volume and elevated FKBP5 expression were signiﬁcantly corre-
lated, and the primary predictor of clinical improvement was
increased FKBP5 expression. We found smaller volumes of mOFC,
but not amygdala, in PTSD at both assessments (before and
after CBT).
The hippocampus may have a multifaceted role in the patho-
genesis of PTSD. First, it participates in the formation of memory
traces for contextual information of traumatic events (i.e., when and
where the trauma happened), providing a representation of safety
or danger of the environment (51). Second, the primate anterior
hippocampus is essential in emotional stress response, with
inhibitory pathways to the hypothalamic nuclei that regulate the
secretion of cortisol. Novel evidence from gene expression proﬁling
and anatomical connectivity suggests that the rodent dorsal
(posterior in primates) hippocampus is linked to cortical regions
participating in learning and spatial-contextual representation,
whereas the ventral (anterior in primates) hippocampus is func-
tionally associated with the amygdala and hypothalamus (52).
Although pioneering structural imaging studies indicated that stress
led to hippocampal atrophy (5,6,16,17), more recent studies raised
the possibility that small hippocampal size is a premorbid vulner-
ability factor for PTSD (26) and larger hippocampal size is associated
with clinical recovery (53). Admon et al. (54) showed that soldiers
with decreased hippocampal volume after military service had more
PTSD-related symptoms than those with increased hippocampal
volume. Vermetten et al. (55) demonstrated that treatment with
paroxetine, a selective serotonin reuptake inhibitor antidepressant,
was accompanied by increased hippocampal volume in PTSD.
Although a previous study did not detect hippocampal
volume changes during CBT (14), we found a signiﬁcant volume
expansion during a 12-week treatment period, which correlated
with clinical improvement. The discrepancy between the negativewww.sobp.org/journal
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explained by differences in patient populations (e.g., chronic
features, presence of depression), sample size, and time passed
since trauma; in the present study, we included less severely
affected, recent-onset patients without comorbidity and with
negative history of psychiatric disorders. This suggests that early
intervention is especially important by targeting potentially more
viable neuroplastic capacities. However, at the same time, it is
dubious whether our ﬁndings can be generalized to chronic and
more severely affected patients. Less severe depressive symptoms
with relatively low variance may also explain a lack of correlation
between imaging data and Hamilton Depression Rating Scale
scores.
We also found a correlation between changes in hippocampal
volume and FKBP5 expression, which were both associated with
clinical improvement. However, regression analyses indicated that
FKBP5 expression change was the primary predictor. Given that
FKBP5 is a regulator protein of the cortisol receptor (18) and
abnormal cortisol secretion is linked to hippocampal atrophy
(16,17), it is reasonable to hypothesize that the amelioration of
FKBP5 gene expression had a causal role in the normalization of
hippocampal volume. Possible mechanisms may be enhanced
neurogenesis, increased neuronal size, and enrichment of den-
dritic arborization (16–18,56). Intriguingly, it may occur together
with an unaltered cortisol level, which is modulated by the
polymorphisms of the FKBP5 gene (57). The other direction of
causality, presupposing that increased hippocampal size led to the
improvement of FKBP5 expression via its regulatory role on the
hypothalamic-pituitary-adrenal stress axis, is less likely. Possible
causal relationships, however, need to be conﬁrmed directly.
This study has limitations. First, we did not use a randomized
controlled design, and therefore it remained unclear whether the
effects were speciﬁcally caused by CBT or spontaneous symptom
improvement. Second, brain imaging was conﬁned to predeﬁned
brain regions, providing no information about the structure and
function of large-scale neuronal networks. We were not able to
investigate functional and structural subdivisions of the hippo-
campal formation.
Hippocampal volume was slightly reduced in control sub-
jects during the follow-up phase, but it was not signiﬁcant.
Given that automatic segmentation methods can lead to errors
in the case of small subcortical structures, this is a critical issue.
However, we did not observe such systematic changes in the
case of amygdala, and there was no signiﬁcant correlation
between hippocampal and amygdala volumes (−.1  r  .1).
This is against the possibility of a systematic error. Given that
the control group included highly traumatized individuals
without PTSD, one can speculate that these individuals showed
decreasing hippocampal volume during the follow-up period,
which may be an indicator of PTSD vulnerability in the absence
of full clinical symptoms.
The third limitation is that the study was hypothesis-driven.
These methodological restrictions were necessary to avoid
statistical confounds due to multiple comparisons at this sample
size. Nevertheless, we conducted a control analysis with the
most signiﬁcantly altered molecular factor in PTSD, RPS6K, which
is an abundant signal transduction molecule critical in the
regulation of ribosomes and protein translation, cell growth,
and survival (58). Despite the statistically robust alteration, this
factor was not related to symptom changes and hippocampal
structure, and its role in PTSD is unknown. FKBP5 expression can
be considered as a state marker, which tends to be normalized
along with symptomatic improvement, and therefore it can be awww.sobp.org/journalmarker of actual disease sate. Together with other factors, these
might be useful in the evaluation of vulnerability, diagnosis,
disease progression, and treatment response (25,31).
The ﬁnal limitation to mention is that a subgroup of patients
received benzodiazepines and beta blockers for 4 weeks, which
may have confounded the results. However, patients with PTSD and
control subjects did not differ in smoking and alcohol use habits,
and therefore the confounding effect of these factors was unlikely.
The strengths of the study lie in the recruitment of recent-
onset, unmedicated patients with negative psychiatric history and
the inclusion of trauma-exposed control subjects who were also
assessed twice in a longitudinal design. Our data did not provide
information about the effect of trauma without the development
of PTSD because trauma nonexposed, supernormal individuals (59)
were not included in the study. Nevertheless, the deﬁnitive
difference in hippocampal volume between trauma-exposed con-
trol subjects and patients with PTSD at the ﬁrst assessment was
somewhat unexpected (7), providing evidence that smaller hippo-
campal volume is speciﬁcally associated with fully developed PTSD.
In conclusion, the results of the present study show a
deﬁnitive link between clinical improvement during psychother-
apy, structural changes of the brain, and peripheral expression of
genes responsible for stress response. The results highlight the
potential relevance of these joined mechanisms, together with
the importance of early intervention in PTSD when neuroplastic
capacities may be more viable.
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